BFM
CLDI icon

Boothbay Fund Management’s Calidi Biotherapeutics CLDI Stock Holding History

Boothbay Fund Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23
Closed -$461K – 1777
2023
Q2 		$461K Buy
+23
New +$457K 0.01% 1135
2022
Q3 		– Sell
-45
Closed -$860K – 2275
2022
Q2 		$860K Hold
45
– – 0.02% 890
2022
Q1 		$862K Buy
+45
New +$851K 0.02% 989

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $360M AUM 19.03% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Boothbay Fund Management's CLDI Position: Q3 2023 in Review

Boothbay Fund Management sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 23 shares — an estimated $461K sold.

Boothbay Fund Management first reported a position in CLDI in Q1 2022 and held it in 3 quarters. The position peaked at $862K in Q1 2022. 10 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • Boothbay Fund Management reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 23 Calidi Biotherapeutics shares in Q3 2023, an estimated $461K.
  • Boothbay Fund Management first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 3 quarters.
  • Boothbay Fund Management's Calidi Biotherapeutics position peaked at $862K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.